BUSINESS SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2011

Segment Reporting [Abstract]

Net sales of key products [Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions		2011		2010		2011		2010
PLAVIX*		$	1,788	$	1,658	$	5,415	$	4,951
AVAPRO*/AVALIDE*			216		303		757		924
ABILIFY*			691		608		2,021		1,858
REYATAZ			391		375		1,153		1,105
SUSTIVA Franchise			359		342		1,073		1,008
BARACLUDE			311		228		878		667
ERBITUX*			172		159		510		497
SPRYCEL			211		144		576		407
YERVOY			121		-		216		-
ORENCIA			233		184		660		531
NULOJIX			-		-		2		-
ONGLYZA/KOMBIGLYZE			127		47		320		85
Mature Products and All Other			725		750		2,209		2,340
	Net Sales	$	5,345	$	4,798	$	15,790	$	14,373

Reconciliation to earnings before income taxes [Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in Millions	2011		2010		2011		2010
BioPharmaceuticals segment income	$	1,347	$	1,186	$	3,934	$	3,599
Reconciling items:
Restructuring and other charges		(20)		(63)		(159)		(395)
Litigation (charges)/recoveries		-		(22)		102		(22)
Upfront, milestone and other licensing payments		(69)		-		(207)		(72)
In-process research and development (IPRD) impairment		(13)		-		(28)		-
Product liability charges		(10)		(13)		(36)		(13)
Noncontrolling interest		595		526		1,781		1,561
Earnings before income taxes	$	1,830	$	1,614	$	5,387	$	4,658